Retrospective Database Study of Real World Abilify Outcomes in Major Depressive Disorder (MDD)
Completed
- Conditions
- Depressive Disorder, Major
- Registration Number
- NCT01284218
- Brief Summary
To examine the differences in health care utilization and costs between MDD patients on adjunctive aripiprazole therapy and MDD patients on other augmentation therapies.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 23514
Inclusion Criteria
- ≥1 fill for an augmentation therapy medication from Table 1 during the identification period of 01 January 2005 - 30 November 2008.
- 12 months of continuous enrollment with medical and pharmacy benefits each before the index date (pre-index period) and after the index date (post-index period).
- ≥1 medical claim with a primary International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) diagnosis for MDD (296.2x, 296.3x, 311.xx) during the pre-index period.
- Age ≥18 years as of the year of the pre-index period.
Exclusion Criteria
- No pharmacy claims for atypical antipsychotics, mood stabilizers, anxiolytics, anticonvulsants, or stimulants, during the pre-index period.
- No medical claims with primary or secondary diagnoses for non-MDD episodic mood disorders or schizophrenia during the pre-index or post-index periods.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method All cause health care costs 12 months
- Secondary Outcome Measures
Name Time Method Therapy switches to a non-index antidepressant or non-index augmentation therapy 12 months Duration of index therapies 12 months Discontinuation of index therapies 12 months Health care resource utilization: All cause, MDD related, mental health related 12 months Health care costs: MDD related, mental health related 12 months Medication possession ratio to evaluate adherence 12 months